Literature DB >> 33489197

Thrombocytosis with acquired von Willebrand disease in an adolescent with sickle cell disease.

Marianne E M Yee1,2, Glaivy Batsuli1,2, Satheesh Chonat1,2, Sunita Park3.   

Abstract

Thrombocytosis is common in sickle cell disease and may contribute to vaso-occlusion. Hydroxyurea treats extreme thrombocytosis. Acquired von Willebrand disease should be considered prior to aspirin therapy.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acquired Von Willebrand disease; priapism; sickle cell disease; thrombocytosis

Year:  2020        PMID： 33489197      PMCID： PMC7813102          DOI： 10.1002/ccr3.3556

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN： 2050-0904


  19 in total

Review 1.  Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.

Authors:  Rebecca F McClure; Mark D Ewalt; Jennifer Crow; Robyn L Temple-Smolkin; Mrudula Pullambhatla; Rachel Sargent; Annette S Kim
Journal:  J Mol Diagn       Date:  2018-08-20       Impact factor: 5.568

2.  Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation.

Authors:  Nicole Kucine; Aaron D Viny; Raajit Rampal; Michael Berger; Nicholas Socci; Agnes Viale; James B Bussel; Ross L Levine; Franck Rapaport
Journal:  Haematologica       Date:  2016-03-18       Impact factor: 9.941

3.  Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.

Authors:  Nya D Nelson; Andrea Marcogliese; Katie Bergstrom; Michael Scheurer; Donald Mahoney; Alison A Bertuch
Journal:  Pediatr Blood Cancer       Date:  2016-04-21       Impact factor: 3.167

4.  Associations of reactive thrombocytosis with clinical characteristics in pediatric diseases.

Authors:  Jinn-Li Wang; Liang-Ti Huang; Kuan-Hsun Wu; Hui-Wen Lin; Man-Yan Ho; Hsingjin Eugene Liu
Journal:  Pediatr Neonatol       Date:  2011-08-04       Impact factor: 2.083

5.  Acquired von Willebrand disease in patients with high platelet counts.

Authors:  U Budde; P J van Genderen
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

6.  The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.

Authors:  Caroline J McNamara; Tony Panzarella; James A Kennedy; Andrea Arruda; Jaime O Claudio; Georgina Daher-Reyes; Jenny Ho; Nancy Siddiq; Rebecca Devlin; Hubert Tsui; Jie Su; Tracy Stockley; Mahadeo Sukhai; Nisha Kanwar; Steven Chan; Dawn Maze; Aaron Schimmer; Andre Schuh; Hassan Sibai; Auro Viswabandya; Karen Yee; Mark D Minden; Suzanne Kamel-Reid; Vikas Gupta
Journal:  Blood Adv       Date:  2018-10-23

7.  Predictive value of absent bone marrow iron stores in the clinical diagnosis of iron deficiency anemia.

Authors:  Apar Kishor Ganti; Nauman Moazzam; Sandeep Laroia; Ketki Tendulkar; Anil Potti; Syed A Mehdi
Journal:  In Vivo       Date:  2003 Sep-Oct       Impact factor: 2.155

8.  SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.

Authors:  Chien-Chin Lin; Hsin-An Hou; Wen-Chien Chou; Yuan-Yeh Kuo; Shang-Ju Wu; Chieh-Yu Liu; Chien-Yuan Chen; Mei-Hsuan Tseng; Chi-Fei Huang; Fen-Yu Lee; Ming-Chih Liu; Chia-Wen Liu; Jih-Luh Tang; Ming Yao; Shang-Yi Huang; Szu-Chun Hsu; Bor-Sheng Ko; Woei Tsay; Yao-Chang Chen; Hwei-Fang Tien
Journal:  Am J Hematol       Date:  2014-04-28       Impact factor: 10.047

9.  IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Authors:  A Tefferi; T L Lasho; O Abdel-Wahab; P Guglielmelli; J Patel; D Caramazza; L Pieri; C M Finke; O Kilpivaara; M Wadleigh; M Mai; R F McClure; D G Gilliland; R L Levine; A Pardanani; A M Vannucchi
Journal:  Leukemia       Date:  2010-05-27       Impact factor: 12.883

10.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.